Advantagene, Inc. d.b.a. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors.
Market
Solid tumors
Location
Auburndale,
MA,
USA
Coinvestors
H7 Holdings, Level One Partners, Northpond Ventures, Sands Capital